– KVD900 Data Accepted for Late Breaking Poster Session –
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--May 29, 2018--
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage
pharmaceutical company focused on the discovery, development, and
commercialization of small molecule protease inhibitors, today announced
data from a poster presentation at the European Academy of Allergy and
Clinical Immunology (EAACI) Congress 2018 in Munich, Germany.
“We are pleased to have developed a proprietary immunoassay to
characterize the effects of our novel orally-available plasma kallikrein
inhibitor, KVD900, in development for treatment of hereditary
angioedema, or HAE,” said Andrew Crockett, Chief Executive Officer of
KalVista. “Using this method, we are able to demonstrate that KVD900
protects high molecular weight kininogen from plasma kallikrein mediated
cleavage in HAE and control plasma. We look forward to providing an
update on our HAE portfolio in the next few months.”
HAE is a rare genetic disease associated with intermittent attacks of
vasogenic edema. This edema is mediated by excessive plasma kallikrein
(PK)-mediated cleavage of high molecular weight kininogen (HK),
resulting in the overproduction of bradykinin. Previous reports have
shown that changes in plasma HK levels provide a clinically useful
biomarker for HAE attacks and efficacy of therapeutics. There are
currently no automated methods to quantify HK in plasma. KalVista
developed a high throughput and semi-automated capillary-based
immunoassay for the quantification of HK in human plasma. Using this new
method, we demonstrate that our novel orally-available PK inhibitor,
KVD900, provides dose dependent protection against HK cleavage in both
HAE and heathy control human plasma in which PK is activated ex vivo
with dextran sulfate. In enzyme assays, we demonstrate that the Ki of
KVD900 in 3 nanomolar (nM) against purified human plasma and its IC50 is
19 nM against plasma kallikrein in a plasma assay.
KVD900 is currently being studied in a Phase 1 trial in healthy
volunteers to evaluate the safety, tolerability and exposure of the drug
candidate. Plasma-based assays for PK will be used to assess its
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on
the discovery, development, and commercialization of small molecule
protease inhibitors for diseases with significant unmet need. The
initial focus is on inhibitors of plasma kallikrein, which is an
important component of the body’s inflammatory response and which, in
excess, can lead to increased vascular permeability, edema and
inflammation. KalVista has developed a proprietary portfolio of novel,
small molecule plasma kallikrein inhibitors initially targeting
hereditary angioedema (HAE) and diabetic macular edema (DME). The
Company has created a structurally diverse portfolio of oral plasma
kallikrein inhibitors and is advancing multiple drug candidates into
Phase 1 clinical trials for HAE. KalVista’s most advanced program, an
intravitreally administered plasma kallikrein inhibitor known as KVD001,
has successfully completed its first-in-human study in patients with DME
and began a Phase 2 clinical trial in 2017.
For more information, please visit www.kalvista.com.
This press release contains "forward-looking" statements within the
meaning of the safe harbor provisions of the U.S. Private Securities
Litigation Reform Act of 1995. Forward-looking statements can be
identified by words such as: "anticipate," "intend," "plan," "goal,"
"seek," "believe," "project," "estimate," "expect," "strategy,"
"future," "likely," "may," "should," "will" and similar references to
future periods. These statements are subject to numerous risks and
uncertainties that could cause actual results to differ materially from
what we expect. Examples of forward-looking statements include, among
others, available funding, our cash runway and future clinical trial
timing and results. Further information on potential risk factors that
could affect our business and its financial results are detailed in the
annual report on Form 10-K filed on July 27, 2017, our most recent
Quarterly Report on Form 10-Q, and other reports as filed from time to
time with the Securities and Exchange Commission. We undertake no
obligation to publicly update any forward-looking statement, whether
written or oral, that may be made from time to time, whether as a result
of new information, future developments or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180529005380/en/
Source: KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc.
Leah Monteiro, 857-999-0808
Corporate Communications & Investor Relations